Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016–2019)
Carlos Roca, Nuria E. Campillo
Expert Opinion on Therapeutic Patents (2020) Vol. 30, Iss. 11, pp. 863-872
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases
Li Wang, Jiajia Li, Li‐jun Di
Medicinal Research Reviews (2021) Vol. 42, Iss. 2, pp. 946-982
Open Access | Times Cited: 124
Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward
Sara Arciniegas Ruiz, Hagit Eldar-Finkelman
Frontiers in Molecular Neuroscience (2022) Vol. 14
Open Access | Times Cited: 81
Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration
Ido Rippin, Hagit Eldar-Finkelman
Cells (2021) Vol. 10, Iss. 2, pp. 262-262
Open Access | Times Cited: 76
GSK-3β: An exuberating neuroinflammatory mediator in Parkinson's disease
Sabiya Samim Khan, Sushmita Janrao, Saurabh Srivastava, et al.
Biochemical Pharmacology (2023) Vol. 210, pp. 115496-115496
Open Access | Times Cited: 40
Immunometabolism in cancer: basic mechanisms and new targeting strategy
Ranran Su, Yingying Shao, Manru Huang, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 10
Odontogenic differentiation of dental pulp stem cells by glycogen synthase kinase-3β inhibitory peptides
Vidhyashree Rajasekar, Mohamed Mahmoud Abdalla, Mohammed S. Basbrain, et al.
Stem Cell Research & Therapy (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Glycogen synthase kinase-3: A potential target for diabetes
Divya Teli, Anuradha K. Gajjar
Bioorganic & Medicinal Chemistry (2023) Vol. 92, pp. 117406-117406
Closed Access | Times Cited: 22
Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors
Husam Nassar, Wolfgang Sippl, Rana Abu‐Dahab, et al.
RSC Advances (2023) Vol. 13, Iss. 17, pp. 11278-11290
Open Access | Times Cited: 17
Glycogen synthase kinase-3: A potential immunotherapeutic target in tumor microenvironment
Jingyi Liang, Meng Yu, Yunong Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116377-116377
Open Access | Times Cited: 7
GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
Beatrice Balboni, Mirco Masi, Walter Rocchia, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7541-7541
Open Access | Times Cited: 13
GSK-3β-mediated regulation of Nrf2/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders
Divya Soni, Puneet Kumar
Pharmacological Reports (2022) Vol. 74, Iss. 4, pp. 557-569
Closed Access | Times Cited: 22
Design, Structure–Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-b]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors
Richard A. Hartz, Vijay T. Ahuja, Prasanna Sivaprakasam, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 4231-4252
Closed Access | Times Cited: 12
Neuroprotective Effect of NO-Delivery Dinitrosyl Iron Complexes (DNICs) on Amyloid Pathology in the Alzheimer’s Disease Cell Model
Wen-Han Chuang, Yu‐Ting Chou, Yihong Chen, et al.
ACS Chemical Neuroscience (2023) Vol. 14, Iss. 16, pp. 2922-2934
Closed Access | Times Cited: 11
The duality of GSK-3β in urinary bladder cancer: Tumor suppressor and promoter roles through multiple signaling pathways
Zufa Sabeel, Jianfeng Wang, Jian Dong, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189324-189324
Closed Access
Synthesis and biological evaluation of thieno[3,2-c]pyrazol-3-amine derivatives as potent glycogen synthase kinase 3β inhibitors for Alzheimer’s disease
Ning Yan, Fei Xie, Long‐Qian Tang, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106663-106663
Open Access | Times Cited: 10
Radiosynthesis and evaluation of a novel 18F-labeled tracer for PET imaging of glycogen synthase kinase 3
Zhiwei Xiao, Yinlong Li, Ahmed Haider, et al.
American Journal of Nuclear Medicine and Molecular Imaging (2024) Vol. 14, Iss. 5, pp. 327-336
Closed Access | Times Cited: 2
Exploring the therapeutic potential of rosemary compounds against Alzheimer’s disease through GC-MS and molecular docking analysis
Anjali Singh, Dhananjay Singh, Neeraj Tiwari, et al.
In Silico Pharmacology (2024) Vol. 12, Iss. 2
Closed Access | Times Cited: 2
Glycogen synthase kinase-3β inhibitor promotes the migration and osteogenic differentiation of rat dental pulp stem cells via the β-catenin/PI3K/Akt signaling pathway
Huilan Xie, Yi Lin, Fang Fang
Journal of Dental Sciences (2021) Vol. 17, Iss. 2, pp. 802-810
Open Access | Times Cited: 14
Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors
Stanislav Andreev, Tatu Pantsar, Roberta Tesch, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 1283-1301
Open Access | Times Cited: 13
Identifying Potential Ligand Binding Sites on Glycogen Synthase Kinase 3 Using Atomistic Cosolvent Simulations
Debarati DasGupta, Ramin Mehrani, Heather A. Carlson, et al.
ACS Applied Bio Materials (2023) Vol. 7, Iss. 2, pp. 588-595
Closed Access | Times Cited: 5
Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3
Víctor Sebastián-Pérez, Paula Martínez de Iturrate, Montserrat Nachér-Vázquez, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1136-1136
Open Access | Times Cited: 7
GSK3 Is a Central Player in Retinal Degenerative Diseases but a Challenging Therapeutic Target
Catherine Hottin, Muriel Perron, Jérôme E. Roger
Cells (2022) Vol. 11, Iss. 18, pp. 2898-2898
Open Access | Times Cited: 7
The Effect of CHIR 99021, a Glycogen Synthase Kinase-3β Inhibitor, on Transforming Growth Factor β-Induced Tenon Fibrosis
Sang Yeop Lee, Min Kyoung Chae, Jin Sook Yoon, et al.
Investigative Ophthalmology & Visual Science (2021) Vol. 62, Iss. 15, pp. 25-25
Open Access | Times Cited: 9
Testing Fmr1KO Phenotypes in Response to GSK3 Inhibitors: SB216763 versus AFC03127
Pamela R. Westmark, Beatrice Garrone, Rosella Ombrato, et al.
Frontiers in Molecular Neuroscience (2021) Vol. 14
Open Access | Times Cited: 7
Kinase inhibition in Alzheimer’s disease
Soghra Bagheri, Ali Akbar Saboury
Elsevier eBooks (2022), pp. 505-533
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top